News

Diabetes prevalence in U.S. adolescents is under 1%


 

FROM JAMA

The prevalence of diabetes among adolescents in the United States is estimated to be 0.8%, with more than a quarter of that group being undiagnosed, according to a research letter published in JAMA.

Using data from the National Health and Nutrition Examination Survey 2005-2014, Andy Menke, PhD, and colleagues estimated the prevalence of diabetes overall, undiagnosed disease, and prediabetes in adolescents aged 12-19 years.

©Tashatuvango/Thinkstockphotos.com

Of the 2,606 adolescents included in the analysis, 62 had diabetes, 20 were undiagnosed, and 512 had prediabetes. The weighted prevalence of diabetes was 0.8% (95% confidence interval, 0.6%-1.1%), of which 28.5% (95% CI, 16.4%-44.8%) was undiagnosed. The researchers defined undiagnosed diabetes as having no report of previous diagnosis but having a hemoglobin A1c level of 6.5% or greater, a fasting plasma glucose level of 126 mg/dL or greater, or a 2-hour plasma glucose level of 200 mg/dL or greater.

The prevalence of prediabetes among the adolescent sample was 17.7% (95% CI, 15.8%-19.8%). Prediabetes was defined as a hemoglobin A1c level of 5.7%-6.4%, a fasting plasma glucose level of 100-125 mg/dL, or a 2-hour plasma glucose level of 140-199 mg/dL among adolescents who did not have diagnosed or undiagnosed diabetes.

“A relatively large proportion was unaware of the condition, particularly among non-Hispanic black participants and Hispanic participants, indicating a need for improved diabetes screening among adolescents,” the researchers wrote. “These findings may have important public health implications because diabetes in youth is associated with early onset of risk factors and complications.”

The researchers were unable to distinguish between types of diabetes, but they noted that previous research in adolescents found that 87% had type 1.

Read the full research letter in JAMA (2016;316[3]:344-5. doi:10.1001/jama.2016.8544).

acruz@frontlinemedcom.com

Recommended Reading

Pediatric cancer survivors at increased risk for endocrine abnormalities
MDedge Endocrinology
New fragility fracture recommendations emphasize coordination of care
MDedge Endocrinology
What difference would an empagliflozin CVD indication make?
MDedge Endocrinology
High rates of early complications seen in youth with diabetes
MDedge Endocrinology
Canagliflozin benefits cohort of type 1 diabetes patients
MDedge Endocrinology
Triple therapy helped type 1 patients improve glycemia
MDedge Endocrinology
Newer insulin glargine formula curbs nocturnal hypoglycemia
MDedge Endocrinology
Metabolic health declining among the obese, despite improvements in BP and lipids
MDedge Endocrinology
Infections, antibiotics more common in type 2 diabetes
MDedge Endocrinology
Study examines long-term trends in type 2 diabetes medication use
MDedge Endocrinology